James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Helios and Matheson Analytics Inc: A Two-Day Ten-Bagger or Mirage?

Helios and Matheson Analytics (HMNY) may be red hot, but with more questions than answers on the table, the smart-money move is taking the money and running.

Why Biogen Inc (BIIB), LendingClub Corp (LC) and Valeant Pharmaceuticals Intl Inc (VRX) Are Three of Today’s Worst Stocks

Biogen (BIIB), LendingClub (LC) and Valeant Pharmaceuticals (VRX) led the parade of losers on Tuesday, but for understandable reasons.

Biogen Inc: BIIB Loses $8B on Drug Failure, But Upside Remains

Biogen (BIIB) is down 12% today on a drug trial's failure, but investors may want to look at a much bigger picture here.

Yahoo! Inc. Should Refuse Verizon Communications Inc.’s Insulting Offer (YHOO VZ)

If Verizon (VZ) is serious about adding the core of Yahoo (YHOO) to its portfolio, it's got a funny way of showing it.

Summer’s Stock Market Forecast: A Chilly S&P 500

The S&P 500 is forging ahead again, but the stock market is facing three major headwinds that will keep a cap on any rally effort.